Recombinant ACE2 can protect mice from severe acute lung injury by blocking SARS-CoV from binding to the membrane-bound form of ACE2 in pneumocytes, which suggests that soluble ACE2 may have a therapeutic potential for treatment of SARS 15, as well as COVID-19. The gene discussed is ACE2; the disease is severe acute respiratory syndrome.